The Lupus Research Institute is among the 333 patient organizations that signed the “I Am (Still) Essential” letter to the U.S. Department of Health and Human Services (HHS) calling for immediate measures to improve how the Affordable Care Act is implemented in the coming year.
Before asking Congress to budget for lupus research, our advocates got the facts. Following summarizes what we learned so you can also know what we are fighting for and why we need Congressional support.
The LRI and S.L.E. Lupus Foundation congratulate Dr. Daniel Wallace on his appointment as consultant to XTL Biopharmaceuticals Ltd. for the planned Phase II trial for the Company's hCDR1 compound for lupus.